Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1413TiP - LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Herbert Loong

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

H.H.F. Loong1, K. Goto2, Y.Y. Elamin3, B. Solomon4, F.C. Santini5, V. Soldatenkova6, A. Sashegyi6, A. Bence Lin6, B.K. Lin6, J. Wolf7, G.R. Oxnard8, C. Zhou9, A. Drilon10, K. Park11

Author affiliations

  • 1 Clinical Oncology, The Chinese University of Hong Kong, - - Shatin/HK
  • 2 A, National Cancer Center Hospital East, Kashiwa/JP
  • 3 Thoracic/head And Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 4 Department Of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne/AU
  • 5 Oncology Center, Hospital Sirio Libanes, 01307-000 - Sao Paulo/BR
  • 6 Oncology, Eli Lilly and Company, 46285 - INDIANAPOLIS/US
  • 7 Oncology, University Hospital Cologne, Cologne/DE
  • 8 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 9 Oncology Department, Shanghai Pulmonary Hospital, 200433 - Shanghai/CN
  • 10 Early Drug Development Service, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, 10065 - New York/US
  • 11 Div. Of Heamatology/oncology, Medicine, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
More

Resources

Abstract 1413TiP

Background

Platinum-based chemotherapy +/- an immune checkpoint inhibitor, the current standard of care in patients (pts) with RET+ NSCLC, does not account for underlying oncogenic drivers. In the LIBRETTO-001 phase 1/2 trial, selpercatinib (Loxo-292), a selective and potent RET inhibitor, demonstrated antitumor activity [objective response rate (ORR) 85%] with a tolerable profile in pts with Tx-naïve, RET+ NSCLC. This global, open-label, randomized, controlled, phase 3 trial will evaluate selpercatinib vs platinum-based and pemetrexed (pem) Tx with or without pembrolizumab (+/-pembro) in Tx-naïve pts with advanced or metastatic RET+ non-squamous NSCLC.

Trial design

Pts will be randomized to Arm A: selpercatinib 160 mg BID in continuous 3 week (wk) cycles or Arm B: pem (500 mg/m2 IV) in 3 wk cycles plus investigator’s choice of carboplatin (carbo) (AUC 5) or cisplatin (cis) (75 mg/m2 IV) for 4 cycles. For Arm B, at the investigator’s discretion, pembro (200 mg IV) may also be given for up to 35 cycles and pts may receive maintenance pem +/-pembro. Crossover is allowed for Arm B pts who progress. Tx will continue until PD, unacceptable toxicity, decision to withdraw or death. Stratification factors are geography: East vs non-East Asian, brain metastases: yes vs no and intended Tx for Arm B: +/-pembro. Eligibility criteria are age ≥18 years; Tx-naïve; non-squamous Stage IIIB-IIIC not suitable for surgery/radiation therapy or Stage IV NSCLC; RET+ identification by PCR or NGS (tumor) or NGS (blood); measurable disease by RECIST 1.1; ECOG performance status 0-2. Key exclusion criteria are presence of other oncogenic drivers or symptomatic CNS metastases. Efficacy assessments will be performed until PD, the start of a new anticancer Tx, death or study completion. The primary endpoint is progression free survival (PFS) per RECIST 1.1 by independent review. Investigator assessed PFS, ORR/duration of response (DOR), intracranial ORR/DOR, overall survival (OS), time to deterioration in pulmonary symptoms, PFS2, RET fusion status: local vs central, safety and pharmacokinetics are secondary endpoints.

Clinical trial identification

NCT04194944.

Editorial acknowledgement

Hannah Davis, PhD, an Eli Lilly and Company employee, provided medical writing support.

Legal entity responsible for the study

Eli Lilly and Company.

Funding

Eli Lilly and Company.

Disclosure

H.H.F. Loong: Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Celgene ; Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Bayer; Speaker Bureau/Expert testimony: Guardant Health; Speaker Bureau/Expert testimony: Eisai; Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck, Sharp & Dohme; Research grant/Funding (institution): Mundipharma; Travel/Accommodation/Expenses: Pfizer. K. Goto: Honoraria (self), Research grant/Funding (self): Astellas Pharma Inc; Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Honoraria (self), Research grant/Funding (self): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (self): Chugai Pharma; Honoraria (self), Research grant/Funding (self): Daiichi Sankyo; Honoraria (self): Guardant Health Inc; Honoraria (self): IQVIA Services Japan K.K.; Honoraria (self), Research grant/Funding (self): Janssen Pharmaceutical K.K. ; Honoraria (self), Research grant/Funding (self): Kyowa Hakko Kirin Co.,Ltd; Honoraria (self), Research grant/Funding (self): Life Technologies; Honoraria (self), Research grant/Funding (self): Lilly; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self), Research grant/Funding (self): Nippon Kayaku; Honoraria (self), Research grant/Funding (self): Novartis; Honoraria (self), Research grant/Funding (self): Ono Pharmaceutical; Honoraria (self): Otsuka Pharmaceutica; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self), Research grant/Funding (self): Taiho Pharmaceutical; Honoraria (self), Research grant/Funding (self): Takeda; Advisory/Consultancy: Otsuka; Research grant/Funding (self): Amgen Inc; Research grant/Funding (self): Loxo; Research grant/Funding (self): Medical & Biological Laboratories Co., Ldt.; Research grant/Funding (self): Merck Serono; Research grant/Funding (self): Riken Genesis; Research grant/Funding (self): Sumitomo Dainippon; Research grant/Funding (self): Sysmex Corporation; Research grant/Funding (self): Xcoo. B. Solomon: Advisory/Consultancy: Roche/Genentech; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Merck; Advisory/Consultancy: Amgen. F.C. Santini: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp Dohme; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy: Lilly; Honoraria (self): Roche; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Novartis. V. Soldatenkova: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly & Company. A. Sashegyi: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly & Company. A. Bence Lin: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly & Company. B.K. Lin: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company. J. Wolf: Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Chugai; Advisory/Consultancy: Lilly; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo/Lilly; Advisory/Consultancy: Amgen; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: Blueprint Medicines. G.R. Oxnard: Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: DropWorks; Advisory/Consultancy: GRAIL; Advisory/Consultancy: Illumina; Advisory/Consultancy: Inivata; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo; Advisory/Consultancy: Merck; Advisory/Consultancy: Sysmex; Advisory/Consultancy: Takeda; Licensing/Royalties: Patent by DFCI, \"Non-invasive blood-based monitoring of genomic alterations in cancer\", on which I am a co-author. C. Zhou: Speaker Bureau/Expert testimony: Lilly China; Speaker Bureau/Expert testimony: Sanofi; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: Hengrui; Advisory/Consultancy, Speaker Bureau/Expert testimony: Qilu; Advisory/Consultancy, Speaker Bureau/Expert testimony: Innovent Biologics; Speaker Bureau/Expert testimony: LUYE Phiosciences Inc; Speaker Bureau/Expert testimony: Amoy Diagnostics; Advisory/Consultancy: Topalliance Biosciences Inc. A. Drilon: Honoraria (self), Research grant/Funding (self): Foundation Medicine; Honoraria (self): Medscape; Honoraria (self), Advisory/Consultancy: MORE Health; Honoraria (self): OncLive; Honoraria (self): Peerview; Honoraria (self): PeerVoice; Honoraria (self): Physicians Education Resources; ; Honoraria (self): Research to Practice; Honoraria (self): Targeted Oncology; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: BeiGene; Advisory/Consultancy: BerGenBio; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Helsinn Therapeutics; Advisory/Consultancy: Hengrui Therapeutics; Advisory/Consultancy: Ignyta; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda/Ariad/Millenium; Advisory/Consultancy: TP Therapeutics; Advisory/Consultancy: Tyra Biosciences; Advisory/Consultancy: Verastem. K. Park: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Amgen; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Hanmi; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo: Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ono Pharmaceutical; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony: AZ; Research grant/Funding (self): MSD Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings